San Francisco Biotech Networks的动态

With major collaborations and partnership deals involving companies like C4 Therapeutics, Inc. , Merck, Monte Rosa Therapeutics and more, and significant progress in the clinic with BTK degraders and other assets, it’s crucial to unite at the 7th TPD & Induced Proximity Summit taking place in Boston this October. The longest standing and most comprehensive protein degradation and proximity conference will span everything from foundational research and discovery to IND-filing and clinical trials, allowing a deep dive into the opportunities and challenges in expanding the target space and developing therapeutically relevant degraders, blockers, stabilisers, and inducers of protein-protein interactions. Uniting over 550 enthusiasts from across the field, we will be providing a comprehensive view of protein degradation and modulation research, including SureTACs, EpiTACs, RIPTACs, Molecular Gates, and more, allowing you to network with experts in the space, benchmark against competitors and stay ahead of the curve. ?? Interested in getting involved? Email me at [email protected] or message me via LinkedIn and I will be happy to share the agenda! #proteindegradation #TPD #targetedproteindegradation #inducedproximity #WomenInTPD #molecularglues #partnershipsinTPD

??Check the comments section for the full News link. ?? Merck Life Science Partners with Aragen Bioscience to Advance mAb Manufacturing ???? Merck Life Science has announced a new collaboration with Aragen Bioscience, marking a significant milestone in the biotech sector. The Memorandum of Understanding (MoU), signed by Aditya Sharma, Head of Process Solutions, India Region, Merck Life Science, and Subodh Deshmukh, CEO of Aragen, aims to accelerate the development of monoclonal antibody (mAb) manufacturing and process solutions. This ?? partnership signifies a crucial step in supporting the development of ??groundbreaking therapies and scaling innovations in the biotech landscape. #MerckLifeScience, #MoU, #Aragen, #MoleculesAndBiologics, #LifeSciences, #DrugDiscovery, #AdityaSharma, #SubodhDeshmukh

In Part 1 of his #BusinessofBiotech interview, with Matthew Pillar and Anna Rose Welch, Tal Zaks, chairman and CEO of Exsilio Therapeutics, discusses the critical role of innovation and intellectual property in the biotech ecosystem. He highlights that while unmet medical needs guide the focus of therapeutic development, the source of true innovation comes from scientific curiosity and technological breakthroughs. He uses the development of lipid nanoparticles as an example of how a foundational scientific discovery can lead to impactful therapies. Dr. Zaks also discusses how return on investment is vital for supporting high-risk innovation, as well as the value of generic medicines and their role in making therapeutics widely available. This thought-provoking discussion sheds light on the drivers of the biotech industry. Watch on YouTube: https://lnkd.in/gZU7CRpg Or watch online: https://lnkd.in/gZaPgP7N #Biotech?#BioPharma #Innovation #IntellectualProperty #ScientificDiscovery?

I am so proud to be part of a team that holds science innovation at the forefront of their business model! Ask me today how our humanized animal models can accelerate your preclinical research. #cancer #humanizedmice #oncology #AACR #immunology

Producing engineered extracellular vesicles for therapeutics applications: in this study, Kristin Luther, Joe Nabhan at Vesigen Therapeutics, Inc. and collaborators evaluated two scalable strategies for generating GFP-loaded ARMM-engineered EVs: transient transfection and stable cell line-based production. The upstream ARMM production processes used a suspension HEK293-derived line called 5B8 from Lonza, with production assessed in both shake flasks and bioreactors. For downstream ARMM purification, they employed Tangential Flow Filtration and Anion Exchange Chromatography https://lnkd.in/eWs8TfSM In vivo, ARMMs demonstrated rapid biodistribution, primarily to the spleen and liver, with lesser distribution to the kidneys and lungs. The successful scale-up of ARMM production highlights the potential of engineered EVs. An article also authored by Ali Navaei, Leah Gens, Carson Semple, Pearl Moharil, Ilaria Passalacqua, Komal Vyas, Qiyu Wang, Shu-Lin Liu, Lucy Sun, Senthil Ramaswamy and Davide Zocco #extracellularvesicles #exosomes #bioengineering #translationalmedicine #cellculture #Vesiculab

#BioBDHighlights Bayer Co.Lab Welcomes Three New Biotech Companies in China On December 10, Bayer announced a strategic collaboration with Epigenic Therapeutics, Immunocan Biotech, and Accuredit Therapeutics 锐正基因（苏州）有限公司, welcoming these three biotechnology companies to join the BayerCo.Lab co-creation platform. Through this partnership, the companies will leverage Bayer's global innovation and collaboration network to connect with industry resources worldwide, accelerating breakthroughs in the fields of cellular therapies and #CGT. This collaboration marks an important step in driving innovation and expanding opportunities in the #biopharma sector. #Bayer #BiotechInnovation #CGT #CellTherapy #CoCreation #BIOCHINA2025 #Partnership

It's one month post-TIDES and we're still on cloud nine from all the great conversations had and data presented.?? Check out this recap below and let us know if you spot Codexis' very own Mathew Miller during his TIDES Talk! Missed our presentations? No problem! Click the link below for the slides from our three presentations, including Derek Gauntlett's talk demonstrating our successful completion of four routes of enzymatic synthesis for inclisiran, and our joint poster with Bachem on enzymatic ligation. #RNAi #TIDESEurope #enzymeengineering Link to Presentations: https://bit.ly/4fpwNbi

?? Exciting September Ahead for CPC Scientific! ?? We’re thrilled to announce that CPC Scientific, a leading manufacturer of oligonucleotides and peptides, will be showcasing our expertise and solutions at several major industry events this September: ?? RNA Leaders (Sept 4-5) ?? ChemOutsourcing (Sept 3-6) ?? Oligonucleotide Therapeutics and Delivery (Sept 9-10) ?? Boulder Peptide Symposium (Sept 16-19) As a trusted partner in oligonucleotide and peptide manufacturing, we look forward to connecting with industry peers, sharing our latest advancements, and exploring new collaborations. Whether you're interested in our advanced oligonucleotide synthesis or innovative peptide solutions, we invite you to visit our booths and meet with our business development team members to discover how CPC Scientific can support your next project. Stay tuned for more details on our participation and how to engage with us. We look forward to seeing you at these exciting events! #CPCScientific #OligonucleotideManufacturing #PeptideManufacturing #ChemOutsourcing #OligonucleotideTherapeutics #RNALeaders #BoulderPeptideSymposium #Biotech #Pharma #Innovation #Networking #TradeShows

MAIA Biotechnology has announced the expansion of its clinical supply agreement with Regeneron for the Phase 2 clinical trial of THIO in combination with cemiplimab (Libtayo?) for advanced #NSCLC patients receiving third-line treatment. In keeping with our clinical strategy for THIO, we look forward to continuing our collaboration with Regeneron to evaluate THIO’s anti-tumor activity when followed by PD-(L)1 inhibition. In case you missed it, read the press release here: https://bit.ly/3VlyUWt #Biotech #Immunotherapy

SFBN Feed: Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases https://lnkd.in/guiX4UPT FOSTER CITY, Calif. & BALLERUP, Denmark–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and [...] #BayArea #SanFrancisco #Biotech #Lifescience #News